Clinical Pharmacokinetics and Pharmacodynamics of Eravacycline

AbstractOn 27 August, 2018, the US Food and Drug Administration approved eravacycline, a fluorocycline antimicrobial agent within the tetracycline class of antibacterial drugs, for the treatment of complicated intra-abdominal infections in patients aged 18  years and older. This decision was based on substantial clinical and pre-clinical data, including rigorous pharmacokinetic and pharmacodynamic work. This paper examines the in-vivo pharmacokinetic/pharmacodynamic work that led to the approval of eravacycline and explores how this important new ant ibiotic may be used to treat aggressive multidrug-resistant infections in the years ahead.
Source: Clinical Pharmacokinetics - Category: Drugs & Pharmacology Source Type: research